[go: up one dir, main page]

AR115015A1 - Derivados de azaespiro piperazina - Google Patents

Derivados de azaespiro piperazina

Info

Publication number
AR115015A1
AR115015A1 ARP190100746A ARP190100746A AR115015A1 AR 115015 A1 AR115015 A1 AR 115015A1 AR P190100746 A ARP190100746 A AR P190100746A AR P190100746 A ARP190100746 A AR P190100746A AR 115015 A1 AR115015 A1 AR 115015A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
members
heterocycloalkyl
heteroaryl
Prior art date
Application number
ARP190100746A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR115015A1 publication Critical patent/AR115015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La presente proporciona, en parte, compuestos de fórmula (1), o un N-óxido del mismo, o una sal farmacéuticamente aceptable del compuesto o el N-óxido, en donde: X¹, X², R¹, R², m y n son como se describe en la presente; procesos para la preparación de; intermediarios usados en la preparación de; y composiciones que contienen dichos compuestos, N-óxidos o sales, y sus usos para tratar trastornos mediados por M4 (o asociados con M4) que incluyen, por ejemplo, enfermedad de Alzheimer, enfermedad de Parkinson, esquizofrenia (por ejemplo, sus síntomas cognitivos y negativos), dolor, adicción y un trastorno del sueño. Reivindicación 1: Un compuesto de fórmula (1), o un N-óxido del mismo, o una sal farmacéuticamente aceptable del compuesto o el N-óxido, en donde: X¹ y X² son cada uno independientemente CH o nitrógeno, siempre y cuando X¹ y X² no sean ambos CH; R¹ se selecciona del grupo que consiste en halógeno, ciano, hidroxi, -SF₅, nitro, -N(R⁶)(R⁷), C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ alquiltio, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, -O-heterocicloalquilo (4 a 6 miembros), C₆₋₁₀ arilo, heteroarilo (5 a 10 miembros) y heterocicloalquilo (4 a 8 miembros), en donde dicho C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ alquiltio, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, -O-heterocicloalquilo (4 a 6 miembros), C₆₋₁₀ arilo, heteroarilo (5 a 10 miembros) y heterocicloalquilo (4 a 8 miembros) están opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados del grupo que consiste en halógeno, ciano, hidroxi, -N(R⁶)(R⁷), C₁₋₆ alquilo, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, y heteroarilo (5 a 6 miembros), en donde dicho C₁₋₆ alquilo, C₁₋₆ alcoxi, y heteroarilo (5 a 6 miembros) están opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados del grupo que consiste en halógeno, ciano, hidroxi, C₁₋₆ alquilo y C₁₋₆ alcoxi; R² se selecciona del grupo que consiste en hidrógeno, halógeno, ciano, hidroxi, -SF₅, nitro, -N(R⁶)(R⁷), C₁₋₆ alquilo, y C₁₋₆ alcoxi, en donde dicho C₁₋₆ alquilo y C₁₋₆ alcoxi están opcionalmente sustituidos con 1 a 3 halógenos; R⁶ y R⁷ se seleccionan, cada uno independientemente, de hidrógeno, C₁₋₆ alquilo o C(O)-CH₃; m es 1 ó 2; y n es 1 ó 2.
ARP190100746A 2018-03-23 2019-03-25 Derivados de azaespiro piperazina AR115015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862647106P 2018-03-23 2018-03-23

Publications (1)

Publication Number Publication Date
AR115015A1 true AR115015A1 (es) 2020-11-18

Family

ID=66102243

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100746A AR115015A1 (es) 2018-03-23 2019-03-25 Derivados de azaespiro piperazina

Country Status (14)

Country Link
US (2) US11524954B2 (es)
EP (2) EP3768669B1 (es)
JP (2) JP7497294B2 (es)
CN (1) CN112154145B (es)
AR (1) AR115015A1 (es)
CA (1) CA3094366A1 (es)
DK (1) DK3768669T3 (es)
ES (1) ES2942837T3 (es)
FI (1) FI3768669T3 (es)
HU (1) HUE061533T2 (es)
PL (1) PL3768669T3 (es)
PT (1) PT3768669T (es)
TW (1) TWI801540B (es)
WO (1) WO2019183636A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020364186B2 (en) 2019-10-09 2023-11-30 Novartis Ag 5-oxa-2-azaspiro(3.4)octane derivatives as M4 agonists
UY38906A (es) 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
KR20210067005A (ko) * 2019-11-28 2021-06-08 제이투에이치바이오텍 (주) 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도
JP2023512762A (ja) * 2020-02-05 2023-03-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド ムスカリン性受容体４アンタゴニストおよび使用方法
JP2024528091A (ja) * 2021-07-30 2024-07-26 ニューロクライン バイオサイエンシーズ，インコーポレイテッド ムスカリン性受容体４アンタゴニストおよび使用方法
WO2024059249A1 (en) * 2022-09-16 2024-03-21 Cerevel Therapeutics, Llc M4 activators/modulators and uses thereof
WO2024151833A1 (en) * 2023-01-12 2024-07-18 Cerevel Therapeutics, Llc Spiro derivatives as m4 activators/modulators and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
EP3150633A1 (en) 2000-02-24 2017-04-05 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
AU3976402A (en) 2000-11-03 2002-06-03 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
BR0315157A (pt) 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
CA2555071A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
KR20070034524A (ko) * 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
ATE493413T1 (de) 2005-05-12 2011-01-15 Pfizer Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006136924A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Histamine-3 receptor antagonists
TW200713011A (en) 2005-09-30 2007-04-01 Hon Hai Prec Ind Co Ltd System, method and electrical apparatus for data transferring
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
US20070107917A1 (en) 2005-11-14 2007-05-17 Doherty Brian J Multifunctional robot tool
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
CN101454320B (zh) 2006-04-21 2012-12-19 辉瑞产品公司 吡啶并[3，4-b]吡嗪酮
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
DK2124933T3 (da) 2007-01-22 2012-11-19 Pfizer Prod Inc Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf
US8664234B2 (en) 2010-10-04 2014-03-04 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators
UA122121C2 (uk) 2014-02-06 2020-09-25 Хептерс Терап'Ютікс Лімітед Біциклічні азотовмісні сполуки як агоністи мускаринового м1 рецептора i/або м4 рецептора
CN106413623B (zh) 2014-03-21 2020-07-03 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
US20210024497A1 (en) 2021-01-28
PT3768669T (pt) 2023-04-24
PL3768669T3 (pl) 2023-07-03
WO2019183636A1 (en) 2019-09-26
EP4219464A1 (en) 2023-08-02
JP2021519269A (ja) 2021-08-10
FI3768669T3 (fi) 2023-04-26
JP7497294B2 (ja) 2024-06-10
CA3094366A1 (en) 2019-09-26
EP3768669B1 (en) 2023-01-25
DK3768669T3 (da) 2023-04-24
ES2942837T3 (es) 2023-06-07
CN112154145B (zh) 2023-10-17
EP3768669A1 (en) 2021-01-27
TW202003491A (zh) 2020-01-16
CN112154145A (zh) 2020-12-29
US11524954B2 (en) 2022-12-13
TWI801540B (zh) 2023-05-11
HUE061533T2 (hu) 2023-07-28
US20230192654A1 (en) 2023-06-22
JP2024037979A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
AR115015A1 (es) Derivados de azaespiro piperazina
AR121661A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
UY37311A (es) Derivados de 5,7-dihidro-pirrolo-piridina
AR115993A2 (es) Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
AR105456A1 (es) Compuestos de piridina con acción fungicida
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
AR117916A1 (es) Compuesto heterocíclico y su uso
AR104487A1 (es) Compuestos de quinolina
AR100154A1 (es) Compuesto heterocíclico que contiene nitrógeno
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
BR112015021336A2 (pt) compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR119234A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1

Legal Events

Date Code Title Description
FB Suspension of granting procedure